146 related articles for article (PubMed ID: 36681053)
1. Zingiberene, a non-zinc-binding class I HDAC inhibitor: A novel strategy for the management of neuropathic pain.
Borgonetti V; Governa P; Manetti F; Galeotti N
Phytomedicine; 2023 Mar; 111():154670. PubMed ID: 36681053
[TBL] [Abstract][Full Text] [Related]
2. Zingiber officinale Roscoe rhizome extract alleviates neuropathic pain by inhibiting neuroinflammation in mice.
Borgonetti V; Governa P; Biagi M; Pellati F; Galeotti N
Phytomedicine; 2020 Nov; 78():153307. PubMed ID: 32846405
[TBL] [Abstract][Full Text] [Related]
3. The new HDAC1 inhibitor LG325 ameliorates neuropathic pain in a mouse model.
Sanna MD; Guandalini L; Romanelli MN; Galeotti N
Pharmacol Biochem Behav; 2017 Sep; 160():70-75. PubMed ID: 28821396
[TBL] [Abstract][Full Text] [Related]
4. Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury.
Borgonetti V; Meacci E; Pierucci F; Romanelli MN; Galeotti N
Neurotherapeutics; 2022 Sep; 19(5):1634-1648. PubMed ID: 35501470
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase as emerging pharmacological therapeutic target for neuropathic pain: From epigenetic to selective drugs.
Zhang W; Jiao B; Yu S; Zhang C; Zhang K; Liu B; Zhang X
CNS Neurosci Ther; 2024 May; 30(5):e14745. PubMed ID: 38715326
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of histone deacetylases and BET family proteins as epigenetic therapy for nerve injury-induced neuropathic pain.
Borgonetti V; Galeotti N
Pharmacol Res; 2021 Mar; 165():105431. PubMed ID: 33529752
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of histone deacetylase inhibitor with novel salicylamide zinc binding group.
Kim JH; Ali KH; Oh YJ; Seo YH
Medicine (Baltimore); 2022 Apr; 101(17):e29049. PubMed ID: 35512065
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics.
Gupta R; Ambasta RK; Kumar P
Life Sci; 2020 Sep; 256():117912. PubMed ID: 32504755
[TBL] [Abstract][Full Text] [Related]
9. HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain.
Denk F; Huang W; Sidders B; Bithell A; Crow M; Grist J; Sharma S; Ziemek D; Rice ASC; Buckley NJ; McMahon SB
Pain; 2013 Sep; 154(9):1668-1679. PubMed ID: 23693161
[TBL] [Abstract][Full Text] [Related]
10. Baicalin ameliorates neuropathic pain by suppressing HDAC1 expression in the spinal cord of spinal nerve ligation rats.
Cherng CH; Lee KC; Chien CC; Chou KY; Cheng YC; Hsin ST; Lee SO; Shen CH; Tsai RY; Wong CS
J Formos Med Assoc; 2014 Aug; 113(8):513-20. PubMed ID: 23684218
[TBL] [Abstract][Full Text] [Related]
11. The analgesic action of larixyl acetate, a potent TRPC6 inhibitor, in rat neuropathic pain model induced by spared nerve injury.
Wang J; Zhao M; Jia P; Liu FF; Chen K; Meng FY; Hong JH; Zhang T; Jin XH; Shi J
J Neuroinflammation; 2020 Apr; 17(1):118. PubMed ID: 32299452
[TBL] [Abstract][Full Text] [Related]
12. Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension.
Kee HJ; Kim I; Jeong MH
Biochem Pharmacol; 2022 Aug; 202():115111. PubMed ID: 35640713
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibition inhibits brachial plexus avulsion-induced neuropathic pain.
Zhao Y; Wu T
Muscle Nerve; 2018 Sep; 58(3):434-440. PubMed ID: 29742796
[TBL] [Abstract][Full Text] [Related]
14. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia.
Bai G; Wei D; Zou S; Ren K; Dubner R
Mol Pain; 2010 Sep; 6():51. PubMed ID: 20822541
[TBL] [Abstract][Full Text] [Related]
16. The HDAC1/c-JUN complex is essential in the promotion of nerve injury-induced neuropathic pain through JNK signaling.
Sanna MD; Galeotti N
Eur J Pharmacol; 2018 Apr; 825():99-106. PubMed ID: 29477655
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors.
Kashyap K; Kakkar R
Comput Biol Med; 2020 Aug; 123():103850. PubMed ID: 32658783
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity.
Ibrahim HS; Abdelsalam M; Zeyn Y; Zessin M; Mustafa AM; Fischer MA; Zeyen P; Sun P; Bülbül EF; Vecchio A; Erdmann F; Schmidt M; Robaa D; Barinka C; Romier C; Schutkowski M; Krämer OH; Sippl W
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008795
[TBL] [Abstract][Full Text] [Related]
19. The Selective CB2 Agonist COR167 Reduced Symptoms in a Mice Model of Trauma-Induced Peripheral Neuropathy through HDAC-1 Inhibition.
Borgonetti V; Mugnaini C; Corelli F; Galeotti N
Biomedicines; 2023 May; 11(6):. PubMed ID: 37371642
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
